कृपया अन्य खोज का प्रयास करें
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Peter Nilsson | 52 | 2014 | Independent Director |
Margitta Seeck | - | - | Member of Scientific Advisory Board |
Annamaria Vezzani | - | - | Member of Scientific Advisory Board |
Gunilla Lundmark | 60 | 2021 | Independent Director |
Per Lundin | 40 | 2020 | Independent Director |
Jonas Ekblom | 58 | 2020 | Independent Chairman of the Board |
Malin Almgren | 47 | 2023 | Independent Director |
Lars Arendt-Nielsen | - | 2023 | Member of Scientific Advisory Board |
Andrew S.C. Rice | - | 2023 | Member of Scientific Advisory Board |
David Bennett | - | 2023 | Member of Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है